Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 439Neoplasms 364Breast Neoplasms 261Colorectal Neoplasms 245Neoplasm Metastasis 217Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 183Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 126Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 98Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Platinum Resistant Ovarian Cancer × Clear all
NCT03319628 2023-11-13

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Mersana Therapeutics

Phase 1/2 Active not recruiting
523 enrolled
GynecologicThoracic

Platinum Resistant Ovarian Cancer

NCT01711970 2020-04-24

A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

Vascular Biogenics Ltd. operating as VBL Therapeutics

Phase 1/2 Completed
38 enrolled
Gynecologic

Platinum Resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡